{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:46:52Z","timestamp":1768880812253,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770004"],"award-info":[{"award-number":["81770004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09201-013"],"award-info":[{"award-number":["2018ZX09201-013"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgar.2020.11.018","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T13:27:33Z","timestamp":1607002053000},"page":"72-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections"],"prefix":"10.1016","volume":"24","author":[{"given":"Yuhang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.jgar.2020.11.018_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious Gram-positive infections","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2020.11.018_bib0010","series-title":"Antibiotic resistance threats in the United States","author":"US Centers for Disease Control and Prevention (CDC)","year":"2013"},{"key":"10.1016\/j.jgar.2020.11.018_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/microorganisms8020191","article-title":"Emerging treatment options for infections by multidrug-resistant Gram-positive microorganisms","volume":"8","author":"Koulenti","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.jgar.2020.11.018_bib0020","series-title":"DALVANCE\u2122 (dalbavancin) for injection, for intravenous use. Initial US approval","author":"US Food and Drug Administration (FDA)","year":"2014"},{"key":"10.1016\/j.jgar.2020.11.018_bib0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2020.11.018_bib0030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp070255","article-title":"Dalbavancin: a new lipoglycopeptide antibiotic","volume":"65","author":"Bailey","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jgar.2020.11.018_bib0035","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/AAC.00274-15","article-title":"In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus isolates from a global surveillance program","volume":"59","author":"McCurdy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.11.018_bib0040","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.11.018_bib0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0091270005280378","article-title":"Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide","volume":"45","author":"Buckwalter","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2020.11.018_bib0050","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.018_bib0055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.018_bib0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in Gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.018_bib0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13756-019-0518-2","article-title":"Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated pneumonia","volume":"8","author":"Zhang","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2020.11.018_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187792","article-title":"Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: results of a network meta-analysis","volume":"12","author":"Guest","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2020.11.018_bib0075","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","article-title":"Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis","volume":"24","author":"Agarwal","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2020.11.018_bib0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2020.11.018_bib0085","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.018_bib0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE Trial","volume":"9","author":"McCarthy","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2020.11.018_bib0095","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.018_bib0100","first-page":"208","article-title":"Efficacy of dalbavancin and telavancin in the treatment of acute bacterial skin and skin structure infections","volume":"13","author":"Nadipelly","year":"2018","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.jgar.2020.11.018_bib0105","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2020.11.018_bib0110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic","volume":"23","author":"David","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2020.11.018_bib0115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2106\/JBJS.N.01350","article-title":"Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009","volume":"97","author":"Kremers","year":"2015","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.jgar.2020.11.018_bib0120","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.11.018_bib0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2020.11.018_bib0130","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.jinf.2013.09.016","article-title":"Which antibiotic for resistant Gram-positives, and why?","volume":"68","author":"Bradley","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2020.11.018_bib0135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00002018-200831090-00004","article-title":"Benefit\u2013risk assessment of linezolid for serious Gram-positive bacterial infections","volume":"31","author":"Falagas","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.jgar.2020.11.018_bib0140","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in Gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2020.11.018_bib0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.018_bib0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of Gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.018_bib0155","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jgar.2020.11.018_bib0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-3-319-11038-7_10","article-title":"Biofilm-based central line-associated bloodstream infections","volume":"830","author":"Yousif","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jgar.2020.11.018_bib0165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgar.2013.03.002","article-title":"Central venous catheter-related biofilm infections: an up-to-date focus on meticillin-resistant Staphylococcus aureus","volume":"1","author":"Esposito","year":"2013","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2020.11.018_bib0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jinf.2004.05.006","article-title":"Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo","volume":"50","author":"Darouiche","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2020.11.018_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114901","article-title":"In vitro time\u2013kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times","volume":"96","author":"Di Pilato","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.11.018_bib0180","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.11.018_bib0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jgar.2019.02.007","article-title":"Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections","volume":"17","author":"Rappo","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2020.11.018_bib0190","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520303040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520303040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:40Z","timestamp":1761991120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520303040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":38,"alternative-id":["S2213716520303040"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.11.018","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}